spr720
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 18, 2018 (NCT03796910)
Timeline
Indications
Mechanism of action
- Gyrase BINHIBITOR
Q6S6F1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05966688 | Phase 1 | Aug 4, 2023 | Spero Therapeutics |
| NCT05955586 | Phase 1 | Aug 1, 2023 | Spero Therapeutics |
| NCT05496374 | Phase 2 | Dec 31, 2022 | Spero Therapeutics |
| NCT04553406 | Phase 1/Phase 2 (Phase 2) | Nov 10, 2020 | Spero Therapeutics |
| NCT03796910 | Phase 1 | Dec 18, 2018 | Simbec-Orion, Spero Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spero Therapeutics | For profit | 5 | 5 | 2 | 2018 |
| Simbec-Orion | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1